Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Biomolecules. 2023 Oct 10;13(10):1500. doi: 10.3390/biom13101500.
Galectin-3 (Gal-3) plays a multifaceted role in the development, progression, and prognosis of pancreatic ductal adenocarcinoma (PDAC). This review offers a comprehensive examination of its expression in PDAC, its interaction with various immune cells, signaling pathways, effects on apoptosis, and therapeutic resistance. Additionally, the prognostic significance of serum levels of Gal-3 is discussed, providing insights into its potential utilization as a biomarker. Critical analysis is also extended to the inhibitors of Gal-3 and their potential therapeutic applications in PDAC, offering new avenues for targeted treatments. The intricate nature of Gal-3's role in PDAC reveals a complex landscape that demands a nuanced understanding for potential therapeutic interventions and monitoring.
半乳糖凝集素-3（Galectin-3）在胰腺导管腺癌（PDAC）的发展、进展和预后中发挥着多方面的作用。本综述全面考察了其在 PDAC 中的表达、与各种免疫细胞的相互作用、信号通路、对细胞凋亡的影响以及治疗耐药性。此外，还讨论了血清 Gal-3 水平的预后意义，探讨了其作为生物标志物的潜在应用。对半乳糖凝集素-3 的抑制剂及其在 PDAC 中的潜在治疗应用也进行了批判性分析，为靶向治疗提供了新的途径。Galectin-3 在 PDAC 中的作用的复杂性揭示了一个复杂的局面，需要深入了解其潜在的治疗干预和监测。
Zotero 插件